Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Q4 2025 value amounting to $9.5 million.

  • Vanda Pharmaceuticals' Other Non-Current Liabilities fell 56.33% to $9.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.5 million, marking a year-over-year decrease of 56.33%. This contributed to the annual value of $9.5 million for FY2025, which is 56.33% down from last year.
  • As of Q4 2025, Vanda Pharmaceuticals' Other Non-Current Liabilities stood at $9.5 million, which was down 56.33% from $11.0 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Other Non-Current Liabilities registered a high of $11.0 million during Q3 2025, and its lowest value of $1.0 million during Q1 2022.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $6.7 million (2022), whereas its average is $6.7 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 6109.23% in 2022, then skyrocketed by 54007.74% in 2023.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Other Non-Current Liabilities stood at $4.4 million in 2021, then soared by 54.9% to $6.8 million in 2022, then rose by 29.81% to $8.8 million in 2023, then rose by 8.61% to $9.6 million in 2024, then dropped by 0.56% to $9.5 million in 2025.
  • Its last three reported values are $9.5 million in Q4 2025, $11.0 million for Q3 2025, and $10.0 million during Q2 2025.